| Literature DB >> 8147101 |
P L Alonso1, M Tanner, T Smith, R J Hayes, J A Schellenberg, M C Lopez, I Bastos de Azevedo, C Menendez, E Lyimo, N Weiss.
Abstract
The development of a safe, affordable and effective malaria vaccine to form part of control schemes in malaria endemic countries is a priority for researchers and public health officials. SPf66 is the first malaria vaccine to have shown partial protection against natural challenge in a phase III trial carried out in a hypoendemic area of Colombia. This paper describes the rationale and design of the first field trial of SPf66 outside South America, and the first to be conducted in an area of high perennial transmission.Entities:
Mesh：
Substances：
Year: 1994 PMID： 8147101 DOI： 10.1016/0264-410x(94)90058-2
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641